Evidence is mounting that links insulin deficiency and insulin resistance to mediation of Alzheimer disease-type neurodegeneration. Get the highlights in these 9 slides.
Incretin Therapy Side Effects Linked to Age, No Metformin Use
GI side effects can lead patients to stop GLP-1 agonist therapy. Identifying risk factors for these adverse events could help improve patient selection.
GLP-1 Agonist Fails to Improve Coronary Flow Reserve in New Study
Incretin-based therapies have shown beneficial effects on the cardiovascular system, providing impetus for this recent study.
SGLT2 Inhibitors: Check Your A1c and BPs
Try this mid-week Q&A on 2 essential properties of the sodium glucose cotransporter 2 (SGLT2) inhibitors.
Dapagliflozin Plus Exenatide: Better Weight Loss Together?
What do you get when you combine an SGLT2 inhibitor and a GLP-1 receptor agonist into therapy for 1 diabetes patient?
Why Do Endocrinologists Burn Out?
Our endo blogger has her theories about why doing what you thought you loved just seems to sap your soul.
A 61-year-old Man with Diabetes and Resistant Hypertension
There are several reasonable options for intensifying this patient's blood pressure treatment. Which one is optimal, though, given his labs and concomitant meds?
Inflammation in Diabetes: What Role for Glucose-lowering Drugs?
Some key classes of antidiabetes agents could play a dual physiologic role. Find out which ones hold most promise in this at-a-glance summary.
Why Don't SGLT2 Inhibitors Inhibit as They Should?
The Paradox: SGLT2 inhibitors should cause 100% inhibition of SGLT2 in humans. They only inhibit by 30%-50%. Why?
SGLT2 Inhibitor Impact on CV Risk: What We Know Now
While we wait for results from FDA-mandated CV outcomes studies by SGLT2I makers, there is plenty of (positive) speculation.
QW GLP-1 RAs: Impact on A1c and Weight
All 3 once-weekly GLP-1 RAs effectively reduce A1c and promote weight loss. Similarities and important differences are parsed in these slides.
What Impact of Weight on GLP-1-stimulated Insulin Secretion?
The size of the incretin effect among healthy subjects may vary up to 2-fold, suggesting differences in ß-cell sensitivity to GLP-1. Does BMI play a role in this variability?
By clicking Accept, you agree to become a member of the UBM Medica Community.